Serenity Medical’s River Stent™ Demonstrates Sustained 4- to 5-Year Benefits in Patients with Idiopathic Intracranial Hypertension (IIH), Presented at SNIS Annual Meeting in Late-Breaking Session
Read more →

NEURONEWS: Long-term data support durability of River stent in IIH treatment

Serenity Medical, a NeuroTechnology Investors (NTI) portfolio company, has announced four-to-five-year results from the RIVER study, which is described as the first multicentre evaluation of the company’s novel venous sinus River stent for the treatment of idiopathic intracranial hypertension (IIH). Read Article.